StockNews.com Begins Coverage on Jaguar Health (NASDAQ:JAGX)

Analysts at StockNews.com began coverage on shares of Jaguar Health (NASDAQ:JAGX – Get Rating) in a research report issued on Monday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Jaguar Health Stock Up 0.1 %

Shares of NASDAQ JAGX opened at $0.08 on Monday. The company has a debt-to-equity ratio of 5.56, a quick ratio of 0.69 and a current ratio of 0.94. Jaguar Health has a 52 week low of $0.08 and a 52 week high of $0.89. The stock has a market capitalization of $12.30 million, a P/E ratio of -0.09 and a beta of 1.73. The stock’s fifty day moving average is $0.11 and its 200 day moving average is $0.18.

Jaguar Health (NASDAQ:JAGX – Get Rating) last issued its quarterly earnings results on Monday, November 14th. The biotechnology company reported ($0.12) EPS for the quarter. Jaguar Health had a negative return on equity of 823.56% and a negative net margin of 502.84%. The company had revenue of $3.15 million during the quarter. Sell-side analysts forecast that Jaguar Health will post -0.64 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of JAGX. Renaissance Technologies LLC bought a new position in Jaguar Health in the first quarter valued at about $1,079,000. Millennium Management LLC grew its position in Jaguar Health by 152.3% in the second quarter. Millennium Management LLC now owns 533,153 shares of the biotechnology company’s stock valued at $157,000 after acquiring an additional 321,795 shares during the last quarter. Bank of New York Mellon Corp grew its position in Jaguar Health by 507.3% in the first quarter. Bank of New York Mellon Corp now owns 169,749 shares of the biotechnology company’s stock valued at $120,000 after acquiring an additional 141,796 shares during the last quarter. Virtu Financial LLC grew its position in Jaguar Health by 76.1% in the first quarter. Virtu Financial LLC now owns 229,270 shares of the biotechnology company’s stock valued at $162,000 after acquiring an additional 99,073 shares during the last quarter. Finally, Citigroup Inc. bought a new position in Jaguar Health in the first quarter valued at about $34,000. Institutional investors own 11.77% of the company’s stock.

Jaguar Health Company Profile

(Get Rating)

Jaguar Health, Inc is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. The firm focuses on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea.